Case Report
This case report discusses daily treatment with silymarin and highlights moderate efficacy and a good safety profile in the management of non-alcoholic steatohepatitis (NASH) and liver function with no side-effects, supporting silymarin as a promising supplemental intervention that can normalize liver activity in non-alcoholic fatty liver disease and NASH.
Case Report
This case report focuses on a patient planning surgery due to lumbar stenosis who was recommended for silymarin treatment, as increased liver enzyme levels were incidentally
found during examination.
Case Report
This case report discusses personalized management of a patient with metabolic-associated fatty liver disease with advanced fibrosis and severe steatosis. The article examines impact of silymarin use, concomitant treatment with diet, exercise, insulin sensitizers and antifibrotic agents.
Case Report
This case report examines silymarin treatment prescribed to a patient with overweight and non-alcoholic fatty liver disease, with an attempt to manage the increased liver enzyme activity levels.
Original Research
Prucalopride is a selective serotonin type 4 (5-HT4) receptor agonist indicated for treatment of chronic idiopathic constipation in adults. 5-HT4 receptors are present in the central nervous system; therefore, this article discusses non-clinical and clinical assessments evaluating the tissue distribution and abuse potential of prucalopride.
